INFLARX N.V.
INFLARX N.V.
Share · NL0012661870 · IFRX · A2H7A5 (XNAS)
Overview Financial Indicators
0,83 USD
1,17 % 0,010 USD
NASDAQ (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 23:29

Current Prices from INFLARX N.V.

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
IFRX
USD
06.06.2025 23:29
0,83 USD
0,83 USD
-0,12 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
0,00 % 5,21 % -47,63 % -30,83 % -68,07 % -48,44 % -88,92 %
Asset Allocation
AssetPercentage %
Stock non-US49,50 %
Stock US49,12 %
Cash1,38 %
NotClassified0,00 %
Other0,00 %
Bond0,00 %
Largest Positions
SymbolISINNamePercentage %
CRLCharles River Laboratories International Inc 6,62 %
TPLTexas Pacific Land Corporation 5,65 %
FNVFranco-Nevada Corporation 4,85 %
PSKPrairieSky Royalty Ltd 4,63 %
DB1Deutsche Börse AG 4,45 %
ASXASX Limited 4,41 %
ICEIntercontinental Exchange Inc 4,25 %
WPMWheaton Precious Metals Corp 4,08 %
ADMArcher-Daniels-Midland Company 3,93 %
MMCMarsh & McLennan Companies Inc 3,43 %
Region Distribution
RegionPercentage %
North America81,33 %
Europe Developed7,36 %
Australasia5,98 %
Asia Developed4,25 %
Japan1,08 %
Africa/Middle East0,00 %
Asia Emerging0,00 %
Europe Emerging0,00 %
Latin America0,00 %
United Kingdom0,00 %
Sector Distribution
SectorPercentage %
Finanzdienstleistungen33,23 %
Grundstoffe22,05 %
Energie18,96 %
Gesundheitswesen8,10 %
Immobilien7,47 %
Basiskonsumgüter5,46 %
Industrieunternehmen2,44 %
Technologie2,30 %
Verbrauchsgüter0,00 %
Telekommunikation0,00 %

Company Profile for INFLARX N.V. Share

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
Fund Master Data
Issuer Horizon Kinetics
Asset Class ETF
Name Horizon Kinetics Inflation Beneficiaries ETF
Fund Currency USD
Category World Large-Stock Growth
fund.
Fund Key Figures
Fund Size 631.168,26 EUR
Investment Strategy
The investment seeks long-term growth of capital in real (inflation-adjusted) terms. The fund is an actively-managed ETF that seeks to achieve its investment objective by investing primarily in the equity securities of domestic and foreign companies that are expected to benefit, either directly or indirectly, from rising prices (inflation). The fund's investments in equity securities are generally expected to include common stock, ownership units of publicly traded MLPs, and units of royalty trusts. The fund is non-diversified.

Company Data

Name INFLARX N.V.
Company InflaRx N.V.
Symbol IFRX
Website https://www.inflarx.de
Primary Exchange XNAS NASDAQ
WKN A2H7A5
ISIN NL0012661870
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Dr. Niels C. Riedemann M.D., Ph.D.
Market Capitalization 70 Mio
Country Germany
Currency USD
Employees 0,1 T
Address Winzerlaer Str. 2, 07745 Jena
IPO Date 2017-11-07

Ticker Symbols

Name Symbol
Frankfurt IF0.F
NASDAQ IFRX

More Shares

Investors who INFLARX N.V. hold also have the following shares in their portfolio:
ADIDAS AG
ADIDAS AG Share
BAIDU INC - ADR
BAIDU INC - ADR Share
BIONTECH SE ADR
BIONTECH SE ADR Share
BYD
BYD Share
GAZPROM ADR
GAZPROM ADR Depository Receipt
JD.CO INC - ADR
JD.CO INC - ADR Share
META PLATFORMS INC
META PLATFORMS INC Share
MICROSOFT CORP
MICROSOFT CORP Share
NATIONWIDE BUILDING SOCIETY 2.15% NTS 16/09/30
NATIONWIDE BUILDING SOCIETY 2.15% NTS 16/09/30 Bond
RIO TINTO
RIO TINTO Share
SQUARE INC A
SQUARE INC A Share
WEICHAI POWER CO
WEICHAI POWER CO Share
WESTINVEST INTERSELECT
WESTINVEST INTERSELECT Fund
X(I)-AI+BIG DATA ETF 1CDL
X(I)-AI+BIG DATA ETF 1CDL ETF
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025